🔗 Share this article

A shadow market for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.

Investigational Drug Gaining Popularity Via Social Media

Retatrutide, which remains in research studies, is being promoted by online personalities for its alleged fat-burning effects. Followers are urged to message these accounts privately for supplier links, while also receiving promotional offers.

Thriving Trade on Social Networks

Separately, a flourishing trade exists on messaging services, where groups with numerous of participants share comparison images, injection guides and claims of next-day British shipping. Vendors market the drug there before directing customers to other platforms for purchases.

Understanding The Experimental Drug

Retatrutide is an experimental injectable created by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the substance is being hailed online as the next Ozempic.

Medical Professionals Express Worries

Nevertheless, physicians and pharmacists have cautions that the distribution of what is still an unlicensed medication in the United Kingdom is a cause for concern and could result in individuals injecting products of uncertain source.

Several professionals said the popularity for retatrutide could be linked to the rising cost of licensed slimming products such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on TikTok or messaging apps is illegal in the UK, as it is an unlicensed drug that cannot be marketed or distributed for human use under the Human Medicines Regulations 2012.

Several influencers attempt to sidestep the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still violate pharmaceutical, marketing, and customer regulations, potentially leading to fines, legal action or imprisonment.

Platform Response and Material Removal

According to the social media company, the platform has taken down problematic material and banned related hashtags and query recommendations. The organization said it was dedicated to maintaining the service secure and allocating resources in strengthening enforcement strategies.

Online Marketplace Activities

Research also found groups with up to 9,000 members selling retatrutide using the platform's built-in search feature, which operates like a public directory. Entering “retatrutide” instantly brings up groups with numerous of members, filled with photos of slimming results, positive testimonials and step-by-step instructions for mixing or administering at residence.

Within minutes of joining one group, a vendor shared contact information, where the majority of purchases take place. The seller sent an guidebook and promised delivery within 48 hours. When questioned whether the substance was authentic, one seller responded: “You can’t be sure.” Another provided a photo of a supposed testing documentation. None asked about weight, medical conditions or previous experience.

Product Information and Costs

Inside these groups, messages display black plastic packages with postal service labels, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with purified liquid, or ready-to-use injectors usually priced at 160 pounds for 20 milligrams. When asked how long a pen should last, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Platform Moderation and Safety Actions

A spokesperson for the messaging service stated it regularly monitored harmful material on its service including material that encouraged the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Medical Professional Cautions

“Individuals are injecting substances they cannot confirm. Even if the science behind this drug is valid, these digital products may not include what they claim,” stated a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the surge in demand to recent price rises for approved slimming drugs such as Mounjaro. “With costs increasing, individuals are using social media. But counterfeit treatments are highly dangerous. You cannot know what’s contained or whether the environment they were produced in was sterile,” she explained.

Her team has already seen individuals harmed by personal administration from unverified sources. “We recognize the disappointment, but buying from Telegram or communication platforms is taking chances with your health,” stated Wyllie. “These materials could be impure or incorrectly dosed.”

Manufacturer Position

A spokesperson from Eli Lilly said retatrutide was in phase 3 clinical trials and had not been reviewed or approved by any government authority anywhere in the world. “Therefore at this time no one can market [it] for personal consumption,” they said, noting that any item “misleadingly claiming itself as a company investigational substance not yet authorized … may subject users to potentially serious health risks”.